POU2F3 CRISPR/Cas9 KO Plasmid (h): sc-417495
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- POU2F3 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the POU2F3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: POU2F3 Antibody (6D1): sc-293402
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
POU2F3 CRISPR/Cas9 KO Plasmid (h) | sc-417495 | 20 µg | $397.00 |
Overview
POU2F3 encodes a POU domain transcription factor that regulates lineage-specific gene expression programs in epithelial cells, with prominent roles in differentiation and maintenance of specialized tuft/brush cell states. By binding octamer-like motifs and coordinating transcriptional networks, POU2F3 influences epithelial identity, sensory-associated signaling, and mucosal barrier-associated processes. Altered POU2F3 activity has been linked to lineage plasticity and subtype-specific transcriptional dependencies in certain epithelial-derived cancers, including small cell lung cancer variants. As a master regulator, it is frequently studied in the context of chromatin-driven cell fate control and transcription factor circuitry rewiring.
POU2F3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the POU2F3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the POU2F3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the POU2F3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish POU2F3 protein expression.
This CRISPR knockout system enables efficient generation of POU2F3-deficient cell models for investigation of POU2F3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting POU2F3 exon(s) critical for POU2F3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple POU2F3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by POU2F3 CRISPR/Cas9 KO Plasmid (h) and POU2F3 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the POU2F3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by POU2F3 HDR Plasmid (h) and POU2F3 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by POU2F3 homology arms to support homology-directed repair at defined POU2F3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.